Vall d’Hebron announce a new strategic research partnership with bioMérieux, a world leader in the field of in vitro diagnostics. This collaboration aims to advance research and development in the areas of infectious diseases, data surveillance, and laboratory automation.

The 4-year partnership, which was signed at the end of 2024, marks a significant milestone in bioMérieux and Vall d’Hebron commitment to innovation and excellence in healthcare.

The collaboration will focus on several key areas of mutual interest in microbiology in particular antimicrobial resistance and stewardship including:

• Data Surveillance: Enhancing automated data collection and surveillance systems at the Catalonia level, leveraging Vall d'Hebron's extensive network.
• Laboratory Automation: Developing automated solutions for reading and interpreting microbiology exams.

Additionally, the collaboration could include antimicrobial susceptibility testing (AST) and the evaluation of new diagnostic solutions.

"We are thrilled to partner with Vall d'Hebron, a leading institution in clinical research and patient care," said Céline Roger-Dalbert, Executive Vice President, R&D at bioMérieux. "This partnership will enable us to combine our expertise and resources, to augment our respective innovation capabilities and to shape future innovative diagnostic solutions for infectious diseases, ultimately contributing to improving patient health."

Vall d'Hebron Barcelona Hospital Campus is a leading healthcare campus located in Barcelona encompassing all fields of health: from healthcare and research to teaching and management. The Vall d’Hebron University Hospital, founded in 1955, is the largest hospital complex in Catalonia and one of the most important healthcare institutions in Spain, and the Vall d’Hebron Research Institute (VHIR) promotes and develops biomedical research, innovation, and teaching at Vall d'Hebron University Hospital. Vall d’Hebron is in particular recognized for its expertise in the field of sepsis management.

"The Microbiology Research Group and the Clinical Microbiology Department at Vall d’Hebron are dedicated to developing research projects that explore microbiological aspects—ranging from basic to translational and clinical research—with the goal of improving outcomes for patients with infectious diseases. Vall d'Hebron is thrilled to collaborate with bioMérieux in this groundbreaking partnership," said Dr. Juanjo González-López, Head of the Microbiology Research Group at VHIR. "Together, we will advance cutting-edge research projects that have the potential to transform the field of infectious diseases and laboratory diagnostics."

This partnership demonstrates bioMérieux’s strategic focus on fostering innovation through collaboration. By working with leading healthcare institutions such as Vall d'Hebron, bioMérieux aims to accelerate the development of cutting-edge diagnostic solutions that address the evolving challenges in infectious disease management. The collaboration will leverage bioMérieux's strengths in diagnostic technologies and Vall d'Hebron's clinical expertise to create impactful solutions that enhance patient care and public health.